Patents by Inventor Katherine Taylor
Katherine Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101984Abstract: Provided herein are CasX:gNA systems comprising CasX polypeptides, guide nucleic acids (gNA), and optionally donor template nucleic acids useful in the modification of a SOD1 gene. The systems are also useful for introduction into cells, for example eukaryotic cells having mutations in the SOD1 protein or the SOD1 regulatory element. Also provided are methods of using such CasX:gNA systems to modify cells having such mutations and utility in methods of treatment of a subject with a SOD1-related disease.Type: ApplicationFiled: February 13, 2023Publication date: March 28, 2024Inventors: Benjamin OAKES, Sean HIGGINS, Hannah SPINNER, Sarah DENNY, Brett T. STAAHL, Kian TAYLOR, Katherine BANEY, Isabel COLIN, Maroof ADIL, Cole URNES
-
Patent number: 11912486Abstract: A package comprising a first panel defining a first end, a second end opposite the first end, and at least two side edges; a second panel defining a first end, a second end opposite the first end, and at least two side edges, wherein the second panel is connected to the first panel via longitudinal seams formed along respective side edges of the first and second panels; and at least one end seam formed along at least one of the first end or the second end of the first and second panels, wherein the at least one end seam comprises an outer edge; and a barrier coating disposed on an interior surface of at least one of the first and second panels, wherein the barrier coating does not extend to the side edges of the longitudinal seams or the outer edge of the at least one end seam.Type: GrantFiled: November 29, 2022Date of Patent: February 27, 2024Assignee: SONOCO DEVELOPMENT, INC.Inventors: Mary Katherine Truitt, Donald Gregory Taylor
-
Publication number: 20230381285Abstract: The present invention provides stable, pure and potent compositions optimized for administration to neonates and/or preterm infants, and use of the same in methods for treating intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD), and/or chronic lung disease of prematurity (CLD), comprising administering to a subject in need of treatment a pharmaceutical composition comprising insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3), and a polysorbate 20 surfactant at high effective doses in low volumes in an infant resulting high serum IGF-1 exposure and treatment of IVH, BPD and/or CLD. In some aspects, provided herein are methods for manufacturing the compositions comprising a single-use bag, wherein the compositions have improved stability, reduced oxidation and increased potency.Type: ApplicationFiled: October 19, 2021Publication date: November 30, 2023Inventors: Nazila SALAMAT-MILLER, Katherine TAYLOR, Bing HE, Indranil BHATTACHARYA, Linda HAN, Benita AMSDEN, James KRANZ
-
Publication number: 20200405825Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.Type: ApplicationFiled: March 24, 2020Publication date: December 31, 2020Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias
-
Publication number: 20200237883Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g., Metachromatic Leukodystrophy Disease). In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 5% of the ASA protein exists in aggregated form.Type: ApplicationFiled: April 17, 2020Publication date: July 30, 2020Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias, Keethkumar Jain, Sujit Basu
-
Patent number: 10660944Abstract: The present invention provides, among oilier things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g. Metachromatic Leukodystrophy Disease), In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 3% of the ASA protein exists in aggregated form.Type: GrantFiled: June 5, 2018Date of Patent: May 26, 2020Assignee: Shire Human Genetic Therapies, Inc.Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias, Keethkumar Jain, Sujit Basu
-
Patent number: 10646554Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.Type: GrantFiled: August 23, 2017Date of Patent: May 12, 2020Assignee: Shire Human Genetic Therapies, Inc.Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias
-
Publication number: 20190323508Abstract: The present disclosure relates to the field of apparatus used in agriculture and irrigation. The existing solutions available with small acreage farmers having access to shallow groundwater are too large or too small in capacity as compared to the size of the farms and have designs which are complicated or unnecessarily expensive. The present disclosure envisages an apparatus (100) which is environment friendly, economical, compact and requires minimum human intervention for operation. The apparatus of the present disclosure (100) has components having dimensions derived from a target specific speed ranging from 600 to 2000 (US unitsārpm, gpm, ft) making the apparatus (100) most suitable and efficient for the afore-stated application.Type: ApplicationFiled: November 22, 2017Publication date: October 24, 2019Inventors: Kevin SIMON, Katherine TAYLOR
-
Publication number: 20190125841Abstract: The present invention provides, among oilier things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g. Metachromatic Leukodystrophy Disease), In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 3% of the ASA protein exists in aggregated form.Type: ApplicationFiled: June 5, 2018Publication date: May 2, 2019Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias, Keethkumar Jain, Sujit Basu
-
Publication number: 20180071212Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.Type: ApplicationFiled: August 23, 2017Publication date: March 15, 2018Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias
-
Patent number: 9770410Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.Type: GrantFiled: June 25, 2011Date of Patent: September 26, 2017Assignee: Shire Human Genetic Therapies, Inc.Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias
-
Publication number: 20140377244Abstract: The present invention provides, among oilier things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g. Metachromatic Leukodystrophy Disease). In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 3% of the ASA protein exists in aggregated form.Type: ApplicationFiled: December 21, 2012Publication date: December 25, 2014Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias, Keethkumar Jain, Sujit Basu
-
Publication number: 20130295071Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an B-Galactocerebrosidase protein, salt, and a polysorbate surfactant for the treatment of GLD Disease.Type: ApplicationFiled: April 12, 2013Publication date: November 7, 2013Inventors: Nazila Salamat-Miller, Katherine Taylor, Ken Manning, Gaozhong Zhu, Paul Campolieto, Zahra Shahrokh, Pericles Calias, Thomas McCauley
-
Publication number: 20120009171Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.Type: ApplicationFiled: June 25, 2011Publication date: January 12, 2012Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias
-
Publication number: 20110318324Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an B-Galactocerebrosidase protein, salt, and a polysorbate surfactant for the treatment of GLD Disease.Type: ApplicationFiled: June 25, 2011Publication date: December 29, 2011Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.Inventors: Nazila Salamat-Miller, Katherine Taylor, Ken Manning, Gaozhong Zhu, Paul Campolieto, Zahra Shahrokh, Pericles Calias, Thomas McCauley
-
Publication number: 20040215466Abstract: A digital audio player with (a) compartment for holding compact discs. This digital audio manipulator has the capability of playing different types of digital audio files from different types of compact discs. This digital audio manipulator can transfer information with computers or other digital audio players.Type: ApplicationFiled: August 6, 2001Publication date: October 28, 2004Inventor: Temeca Katherine Taylor
-
Patent number: D969457Type: GrantFiled: January 15, 2021Date of Patent: November 15, 2022Assignee: LULULEMON ATHLETICA CANADA INC.Inventor: Katherine Taylor Monk
-
Patent number: D980585Type: GrantFiled: August 31, 2020Date of Patent: March 14, 2023Assignee: LULULEMON ATHLETICA CANADA INC.Inventors: Katherine Taylor Monk, Erika Leigh Rekis